Unknown

Dataset Information

0

Aberrant expression of COT is related to recurrence of papillary thyroid cancer.

ABSTRACT: Aberrant expression of Cancer Osaka Thyroid Oncogene mitogen-activated protein kinase kinase kinase 8 (COT) (MAP3K8) is a driver of resistance to B-RAF inhibition. However, the de novo expression and clinical implications of COT in papillary thyroid cancer (PTC) have not been investigated.The aim of this study is to investigate the expression of A-, B-, C-RAF, and COT in PTC (n?=?167) and analyze the clinical implications of aberrant expression of these genes.Quantitative polymerase chain reaction (qPCR) and immunohistochemical staining (IHC) were performed on primary thyroid cancers. Expression of COT was compared with clinicopathological characteristics including recurrence-free survival. Datasets from public repository (NCBI) were subjected to Gene Set Enrichment Analysis (GSEA).qPCR data showed that the relative mRNA expression of A-, B-, C-RAF and COT of PTC were higher than normal tissues (all P?

SUBMITTER: Lee J 

PROVIDER: S-EPMC4602754 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Aberrant expression of Cancer Osaka Thyroid Oncogene mitogen-activated protein kinase kinase kinase 8 (COT) (MAP3K8) is a driver of resistance to B-RAF inhibition. However, the de novo expression and clinical implications of COT in papillary thyroid cancer (PTC) have not been investigated.The aim of this study is to investigate the expression of A-, B-, C-RAF, and COT in PTC (n = 167) and analyze the clinical implications of aberrant expression of these genes.Quantitative polymerase chain reacti  ...[more]

Similar Datasets

Unknown Aberrant expression of PROS1 correlates with human papillary thyroid cancer progression.
| S-EPMC8344691 | biostudies-literature
Unknown Aberrant expression of five miRNAs in papillary thyroid carcinomas.
| S-EPMC8418488 | biostudies-literature
Unknown Comprehensive analysis of aberrant alternative splicing related to carcinogenesis and prognosis of papillary thyroid cancer.
| S-EPMC8544310 | biostudies-literature
Unknown RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence.
| S-EPMC4266707 | biostudies-literature
Unknown Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors.
| S-EPMC9016467 | biostudies-literature
Unknown Aberrant Expression of Androgen Receptor Associated with High Cancer Risk and Extrathyroidal Extension in Papillary Thyroid Carcinoma.
| S-EPMC7281729 | biostudies-literature
Unknown Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer.
| S-EPMC5933725 | biostudies-literature
Unknown Nomogram-Based New Recurrence Predicting System in Early-Stage Papillary Thyroid Cancer.
| S-EPMC6754965 | biostudies-literature
Unknown Recurrence Factors and Characteristic Trends of Papillary Thyroid Cancer over Three Decades.
| S-EPMC8131146 | biostudies-literature
Unknown Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
| S-EPMC6599911 | biostudies-literature